publication date: Feb. 27, 2015

Meir Wetzler, 60, Roswell Park Hematologic Oncologist

 

Meir Wetzler, 60, chief of the Leukemia Section at the Roswell Park Cancer Institute, died Feb. 23, nearly two weeks after a skiing accident in Denver, Colo.

Remembered as a brilliant and compassionate physician, he worked with cooperative groups and pharmaceutical companies to make clinical trials available to leukemia patients at Roswell Park. At the time of his death, he was principal investigator at the institute for clinical trials for CML, acute myeloid leukemia, multiple myeloma and myelofibrosis.

His research focused on autocrine and paracrine growth factor regulatory loops in the pathogenesis of leukemia, and signal transducer and activator of transcription proteins in leukemogenesis.

During his tenure at Roswell Park, he was named numerous times to the Castle Connolly Medical Ltd. list of America’s Top Doctors, most recently this year.

Colleagues remember him as someone who often appeared serious but had a playful side, evidenced every year when he and members of his team dressed in themed costumes and slid into a pool of gelatin to raise money for the Leukemia and Lymphoma Society of Western New York.

Often the team paraded through the Roswell Park inpatient rooms in costume, “because it was good for the patients’ morale to do something fun,” recalled pathology resource technician Linda Lutgen-Dunckley.

“He oversaw clinical activities departmentally and co-chaired the Ambulatory Services Executive Committee,” said Alex Adjei, chair of the Department of Medicine and senior vice-president for clinical research.

“He co-chaired the Scientific Review Committee and chaired the Pharmacy & Therapeutics Committee. Meir also oversaw … Continue reading 41-08 Meir Wetzler, 60, Roswell Park Hematologic Oncologist

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.